Tearsheet
Investment Highlights Market Valuation Price Chart About VRTX Interactive Breakdown Better Bets vs. VRTX Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Vertex Pharmaceuticals (VRTX)

Market Price (10/20/2025): $417.0 | Market Cap: $107.0 Bil
Sector: Health Care | Industry: Biotechnology

Vertex Pharmaceuticals (VRTX)

Market Price (10/20/2025): $417.0
Market Cap: $107.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%, CFO LTM is 3.8 Bil, FCF LTM is 3.5 Bil		 Weak multi-year price returns
2Y Excs Rtn is -42%, 3Y Excs Rtn is -43%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -199 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.7%
1 Low stock price volatility
Vol 12M is 36%		  Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 29x
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%, CFO LTM is 3.8 Bil, FCF LTM is 3.5 Bil
1 Low stock price volatility
Vol 12M is 36%
2 Weak multi-year price returns
2Y Excs Rtn is -42%, 3Y Excs Rtn is -43%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -199 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.7%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 24x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 29x

Market Valuation & Key Metrics

VRTXS&P 500
REVENUE GROWTHGOOD
Rev LTM ($ Bil)11.4
Rev Chg Q12.1%6.1%
Rev Chg LTM10.5%5.2%
Rev Chg 3Y Avg11.0%5.4%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)-0.2
Op Mgn LTM-1.7%18.6%
CFO LTM ($ Bil)3.8
CFO/Rev LTM33.7%20.4%
Net Inc LTM ($ Bil)3.6
Net Inc Mgn31.9%12.7%
VALUATIONHIGH
P/S9.43.2
P/CFO27.815.9
P/FCF30.620.7
P/E29.424.0
STABILITYVERY GOOD
Debt/Equity0.010.22
Cash/Assets0.270.07

VRTX Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
VRTX Return8%-7%32%41%-1%4%90%
Peers Return1%-26%6%29%-36%24%-18%
S&P 500 Return16%27%-19%24%23%13%106%

Monthly Win Rates [3]
VRTX Win Rate67%42%67%58%50%78% 
Peers Win Rate48%46%50%50%29%50% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
VRTX Max Drawdown-9%-25%0%-2%-3%-9% 
Peers Max Drawdown-23%-38%-22%-14%-42%-24% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BIIB, BMRN, IONS, ACAD, ACSB. See VRTX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/17/2025 (YTD)

Downturns Compared

Unique KeyEventVRTXS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-26.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven36.3%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven115 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-31.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven46.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven655 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-21.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven26.9%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven25 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-64.0%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven178.0%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven610 days1480 days


How Low Can It Go?

Vertex Pharmaceuticals's stock fell -26.6% during the 2022 Inflation Shock from a high on 1/25/2021. A -26.6% loss requires a 36.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Better Bets than Vertex Pharmaceuticals (VRTX)

 VRTXBetter Performance than VRTX
MetricValueIndustry (Biotechnology)
Rev Chg LTM10.5%AMGN (12.9%), ALNY (17.2%), INSM (21.2%), UTHR (17.6%), INCY (18.9%)
Rev Chg 3Y Avg11.0%ALNY (40.8%), INSM (21.6%), UTHR (19.9%), INCY (11.5%), NBIX (26.0%)
Op Mgn LTM-1.7%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (27.0%), BIIB (23.2%)
CFO/Rev LTM33.7%AMGN (34.4%), GILD (34.2%), UTHR (44.6%), RPRX (104.4%), EXEL (34.6%)
FCF/Rev LTM30.6%ABBV (31.3%), GILD (32.5%), UTHR (34.8%), RPRX (104.4%), EXEL (32.4%)
Total Yield3.4%ABBV (3.7%), AMGN (7.2%), GILD (6.7%), REGN (7.6%), BIIB (7.1%)
 VRTXBetter Performance than VRTX
MetricValueAll Other Sectors
Rev Chg LTM10.5%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%), META (19.4%)
Rev Chg 3Y Avg11.0%NVDA (92.0%), MSFT (12.5%), AMZN (11.3%), META (13.0%), AVGO (24.0%)
Op Mgn LTM-1.7%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM33.7%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM30.6%NVDA (43.6%), META (30.7%), AVGO (41.6%), V (56.8%), MA (49.2%)
Total Yield3.4%GOOGL (4.1%), META (4.0%), JPM (6.8%), V (3.8%), XOM (9.9%)
 Best Bets In Health Care Sector
 VRTXRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA UHS
What You Pay           
P/E29.415.414.612.014.114.410.614.711.917.110.4
P/EBIT24.48.111.510.39.69.226.110.010.09.37.2
What You Get           
Rev Chg Q12.1%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%9.6%
Rev Chg LTM10.5%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%9.6%
Rev Chg 3Y Avg11.0%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%8.1%
FCF/Rev 3Y Avg19.2%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%4.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Vertex Pharmaceuticals Earnings Notes  
2With Vertex Pharmaceuticals Stock Climbed 7.7% In A Month, How Confident Are You?Return 
3VRTX Slides 17% In A Single Month: Where Does It Rank Among Competitors?  
4Should You Buy Vertex Pharmaceuticals Stock?Buy or Fear 
5Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From BKNG, RCL   
6Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, BMRN   
7Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, BMRN   
8Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, NBIX, EXEL, BMRN Actionable 
9VRTX Dip Buy Analysis  
10Vertex Pharmaceuticals Total Shareholder Return (TSR): -1.0% in 2024 and 22.4% 3-yr compounded annual returns (above peer average)  
11ARTICLES  
12VRTX Dips 17% In One Month: Does It Lead the Pack? August 27th, 2025
13VRTX Dips 16% In One Month, Should You Buy The Stock? August 26th, 2025
14VRTX Down 16% In A Month. How Confident Are You In The Stock? August 26th, 2025
15With VRTX Down 21% in a Day, Is It Time to Compare It Against UTHR? August 6th, 2025
16S&P 500 Stocks Trading At 52-Week Low August 6th, 2025
Title
0DASHBOARDS
1VRTX Dips 17% In One Month: Does It Lead the Pack?
2VRTX Dips 16% In One Month, Should You Buy The Stock?
3VRTX Down 16% In A Month. How Confident Are You In The Stock?
4With VRTX Down 21% in a Day, Is It Time to Compare It Against UTHR?
5S&P 500 Stocks Trading At 52-Week Low
6ARTICLES
7Vertex Pharmaceuticals Earnings Notes
8With Vertex Pharmaceuticals Stock Climbed 7.7% In A Month, How Confident Are You?
9VRTX Slides 17% In A Single Month: Where Does It Rank Among Competitors?
10Should You Buy Vertex Pharmaceuticals Stock?
11Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From BKNG, RCL 
12Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, BMRN 
13Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, BMRN 
14Better Bet Than VRTX Stock: Pay Less Than Vertex Pharmaceuticals To Get More From UTHR, NBIX, EXEL, BMRN 
15VRTX Dip Buy Analysis
16Vertex Pharmaceuticals Total Shareholder Return (TSR): -1.0% in 2024 and 22.4% 3-yr compounded annual returns (above peer average)

Trade Ideas

Select past ideas related to VRTX. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-4.4%-4.4%-8.0%
VRTX_12312022_Quality_Momentum_RoomToRun_10%12312022VRTXVertex PharmaceuticalsQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run		21.9%40.9%-1.9%
VRTX_10312020_Dip_Buyer_ValueBuy10312020VRTXVertex PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.7%-11.2%-15.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-4.4%-4.4%-8.0%
VRTX_12312022_Quality_Momentum_RoomToRun_10%12312022VRTXVertex PharmaceuticalsQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run		21.9%40.9%-1.9%
VRTX_10312020_Dip_Buyer_ValueBuy10312020VRTXVertex PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.7%-11.2%-15.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines256.7%146.9%
2NVTSNavitas Semiconductor78.1%310.6%
3SSIISS Innovations International40.1%23.4%
4FLNCFluence Energy40.0%15.4%
5BTDRBitdeer Technologies35.1%10.8%
6MVSTMicrovast34.6%181.6%
7POWIPower Integrations31.3%-25.4%
8CCOClear Channel Outdoor30.8%24.1%
9IRONDisc Medicine28.7%41.9%
10BEBloom Energy28.4%402.0%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1SOCSable Offshore-35.8%-48.4%
2SRRKScholar Rock-29.2%-35.4%
3AIVApartment Investment & Management-28.3%-9.0%
4ALABAstera Labs-22.5%20.6%
5BYRNByrna Technologies-19.7%-26.6%
6BWINBaldwin Insurance-19.5%-40.3%
7ONDSOndas-17.5%197.3%
8URGUr-Energy-17.4%40.0%
9IIINInsteel Industries-16.4%14.6%
10LIFLife360-16.0%112.3%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1160.2%365.5%
2PRAXPraxis Precision Medicines320.1%146.9%
3QUREuniQure293.5%228.4%
4FLNCFluence Energy131.4%15.4%
5CLPTClearPoint Neuro123.6%65.0%
6NVTSNavitas Semiconductor117.8%310.6%
7LACLithium Americas110.9%128.6%
8ASTSAST SpaceMobile101.5%295.7%
9BETRBetter Home & Finance97.8%610.2%
10GRALGRAIL97.0%337.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-50.9%-48.4%
2FLYFirefly Aerospace-41.7% 
3PGYPagaya Technologies-39.5%185.3%
4UPWheels Up Experience-37.1%-6.7%
5ALABAstera Labs-36.6%20.6%
6VGVenture Global-35.8% 
7USNAUsana Health Sciences-32.3%-41.8%
8UPSTUpstart-31.7%-24.5%
9DOMODomo-30.8%73.6%
10TROXTronox-30.6%-63.2%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines256.7%146.9%
2NVTSNavitas Semiconductor78.1%310.6%
3SSIISS Innovations International40.1%23.4%
4FLNCFluence Energy40.0%15.4%
5BTDRBitdeer Technologies35.1%10.8%
6MVSTMicrovast34.6%181.6%
7POWIPower Integrations31.3%-25.4%
8CCOClear Channel Outdoor30.8%24.1%
9IRONDisc Medicine28.7%41.9%
10BEBloom Energy28.4%402.0%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1SOCSable Offshore-35.8%-48.4%
2SRRKScholar Rock-29.2%-35.4%
3AIVApartment Investment & Management-28.3%-9.0%
4ALABAstera Labs-22.5%20.6%
5BYRNByrna Technologies-19.7%-26.6%
6BWINBaldwin Insurance-19.5%-40.3%
7ONDSOndas-17.5%197.3%
8URGUr-Energy-17.4%40.0%
9IIINInsteel Industries-16.4%14.6%
10LIFLife360-16.0%112.3%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Vertex Pharmaceuticals

Financials

VRTXBIIBBMRNIONSACADACSBMedian
NameVertex P.Biogen BioMarin.Ionis Ph.ACADIA P.Acesis  
Mkt Price416.81143.0053.2973.0920.89-73.09
Mkt Cap107.020.910.211.63.5-11.6
Rev LTM11,4199,8163,0647171,019-3,064
Op Inc LTM-1992,274776-47290-90
FCF LTM3,5002,296691-56388-691
FCF 3Y Avg1,9841,667315-43845-315
CFO LTM3,8462,582767-502188-767
CFO 3Y Avg2,3241,968419-40178-419

Growth & Margins

VRTXBIIBBMRNIONSACADACSBMedian
NameVertex P.Biogen BioMarin.Ionis Ph.ACADIA P.Acesis  
Rev Chg LTM10.5%1.6%18.4%-7.6%14.4%-10.5%
Rev Chg 3Y Avg11.0%-3.1%17.0%-1.4%27.9%-11.0%
Rev Chg Q12.1%6.1%15.9%10.1%9.3%-10.1%
QoQ Delta Rev Chg LTM2.9%1.5%3.8%1.7%2.3%-2.3%
Op Mgn LTM-1.7%23.2%25.3%-65.9%8.9%-8.9%
Op Mgn 3Y Avg26.5%23.4%14.0%-65.7%-3.9%-14.0%
QoQ Delta Op Mgn LTM2.0%0.2%4.3%1.5%-0.0%-1.5%
CFO/Rev LTM33.7%26.3%25.0%-70.0%18.4%-25.0%
CFO/Rev 3Y Avg22.5%20.0%15.0%-59.0%7.1%-15.0%
FCF/Rev LTM30.6%23.4%22.6%-78.5%8.7%-22.6%
FCF/Rev 3Y Avg19.2%16.9%10.9%-64.4%3.8%-10.9%

Valuation

VRTXBIIBBMRNIONSACADACSBMedian
NameVertex P.Biogen BioMarin.Ionis Ph.ACADIA P.Acesis  
Mkt Cap107.020.910.211.63.5-11.6
P/S9.42.13.316.23.4-3.4
P/EBIT24.410.512.0-30.738.8-12.0
P/E29.414.115.6-25.315.8-15.6
P/CFO27.88.113.3-23.118.7-13.3
Total Yield3.4%7.1%6.4%-3.9%6.3%-6.3%
Dividend Yield0.0%0.0%0.0%0.0%0.0%-0.0%
FCF Yield 3Y Avg2.1%6.6%2.7%-7.0%1.5%-2.1%
D/E0.00.30.10.10.0-0.1
Net D/E-0.00.2-0.1-0.1-0.2--0.1

Returns

VRTXBIIBBMRNIONSACADACSBMedian
NameVertex P.Biogen BioMarin.Ionis Ph.ACADIA P.Acesis  
1M Rtn8.8%0.4%-2.0%19.8%-14.5%-0.4%
3M Rtn-9.4%14.4%-7.0%75.0%-7.4%--7.0%
6M Rtn-14.8%20.6%-9.9%157.4%41.8%-20.6%
12M Rtn-13.7%-24.8%-24.0%84.2%36.5%--13.7%
3Y Rtn43.6%-45.6%-39.9%63.0%33.2%-33.2%
1M Excs Rtn7.2%-1.0%-3.8%17.9%-16.1%--1.0%
3M Excs Rtn-14.8%10.9%-11.5%70.2%-11.9%--11.5%
6M Excs Rtn-40.9%-5.6%-36.1%131.2%15.7%--5.6%
12M Excs Rtn-28.5%-39.9%-39.0%78.6%25.5%--28.5%
3Y Excs Rtn-42.6%-129.9%-126.4%-27.5%-52.8%--52.8%

Comparison Analyses

Title
0With 34% Gains On The Table, ACAD May Outshine VRTX
1VRTX Could Deliver 31% Returns And Outperform IONS
2VRTX or BMRN - With 46% Return Forecast, BMRN Probably Deserves Your Money
3Vertex Pharmaceuticals vs. Paychex: With Return Forecast Of 72%, Vertex Pharmaceuticals Is A Better Bet
4Vertex Pharmaceuticals vs. Marriot: With Return Forecast Of 72%, Vertex Pharmaceuticals Is A Better Bet
5Vertex Pharmaceuticals vs. Edwards Lifesciences: With Return Forecast Of 72%, Vertex Pharmaceuticals Is A Better Bet
6Vertex Pharmaceuticals vs. Analog Devices: Similar Revenue, But Vertex Pharmaceuticals Is A Better Bet
7Vertex Pharmaceuticals vs. KLA Tencor: Similar Revenue, But Vertex Pharmaceuticals Is A Better Bet
8Vertex Pharmaceuticals vs. Zoetis: Similar Income, But Vertex Pharmaceuticals Is A Better Bet
9Vertex Pharmaceuticals vs. Autodesk, Inc: Similar Market Cap, But Vertex Pharmaceuticals Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/5/20255/6/20252/13/202511/5/20248/2/20245/7/20242/15/202411/7/20238/2/20235/2/20232/10/202310/28/2022
Key Financials Quarterly            
Total Revenue2,9652,7702,9122,7722,6462,6912,5182,4842,4932,3752,3032,334
Ebitda1,3387821,1861,285-3,3271,3431,2171,2321,2149421,1271,227
Operating Income1,1541,031-3,5161,1329351,2164291,0911,1361,1249421,153
Net Income1,0336469131,045-3,5941,1009691,035916700819930
EPS4.022.523.554.05-13.924.263.764.013.552.723.193.63
Key Financials TTM            
Total Revenue TTM11,41911,10011,02010,62610,33710,1859,8699,6549,5059,2088,9318,701
Ebitda TTM4,591-754865184655,0064,6054,5154,5094,3724,4364,228
Operating Income TTM-199-418-2333,7123,6713,8723,7804,2944,3564,3394,2504,183
Net Income TTM3,638-989-536-480-4904,0193,6203,4703,3653,2603,3223,273
Growth Rates Quarterly            
Total Revenue Growth12.1%3.0%15.7%11.6%6.1%13.3%9.3%6.4%13.5%13.2%11.1%17.7%
EBITDA Growth140.2%-41.8%-2.6%4.3%-374.1%42.6%8.0%0.4%12.8%-6.4%22.5%8.6%
Operating Income Growth23.5%-15.2%-919.8%3.7%-17.7%8.2%-54.5%-5.4%1.5%8.6%7.6%9.2%
Net Income Growth128.7%-41.2%-5.8%1.0%-492.4%57.1%18.3%11.3%13.0%-8.2%6.3%9.2%
Margins Quarterly            
EBITDA Margin45.1%28.2%40.7%46.4%-125.8%49.9%48.3%49.6%48.7%39.7%48.9%52.6%
Operating Income Margin38.9%37.2%-120.7%40.8%35.3%45.2%17.0%43.9%45.6%47.3%40.9%49.4%
Net Income Margin34.8%23.3%31.4%37.7%-135.8%40.9%38.5%41.7%36.7%29.5%35.6%39.9%
Cash & Debt            
Total Cash6,3836,2016,1166,5245,79610,17111,21811,92811,23610,41410,7789,771
Total Debt1,5271,6491,7501,703933721808745768789900825
Net Debt / (Cash)-4,855-4,552-4,366-4,822-4,862-9,450-10,410-11,184-10,469-9,625-9,879-8,946
Cash Flows Quarterly            
FCF from Operations1,0738195851,370-3,7541,3072351,2681,1349001,078956
Cash Flows TTM            
FCF from Operations TTM3,846-980-493-843-9443,9443,5374,3814,0684,0744,1304,046
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases39869742539140136515317031299248
Return on Invested Capital (ROIC) Quarterly            
ROIC359.5%215.8%-463.7%182.7%165.2%-------
Return on Invested Capital (ROIC) TTM            
ROIC TTM-16.0%-24.7%-9.6%175.4%162.1%-------

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
TRIKAFTA/KAFTRIO8,9457,6875,6973,864420
Other product revenues9241,244   
KALYDECO  684803991
ORKAMBI  7729081,332
Other revenues  132
SYMDEKO/SYMKEVI  4206291,418
Total9,8698,9317,5746,2064,163


Price Behavior

VRTX Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta-0.061.121.120.450.470.52
Up Beta2.041.300.970.330.400.48
Down Beta-3.95-0.490.070.220.180.40
Up Capture7%55%77%46%49%26%
Bmk +ve Days13233574144420
Stock +ve Days8203264134417
Down Capture11%278%244%123%95%85%
Bmk -ve Days8192952107330
Stock -ve Days13223161116333

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity3,557,058
Short Interest: % Change Since 9152025-12.2%
Average Daily Volume2,027,132
Days-to-Cover Short Interest1.75
Basic Shares Quantity256,700,000
Short % of Basic Shares1.4%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/4/2025-20.6%-20.7%-16.0%
5/5/2025-10.0%-12.2%-10.9%
2/10/2025-3.1%-1.7%5.4%
11/4/20245.7%6.1%-1.9%
8/1/2024-2.2%-7.9%-2.0%
5/6/20241.9%6.8%20.0%
2/5/2024-3.0%-2.4%-4.0%
11/6/2023-1.9%-1.8%-8.4%
...
SUMMARY STATS   
# Positive121112
# Negative121312
Median Positive2.5%6.1%7.5%
Median Negative-3.1%-2.4%-5.1%
Max Positive9.0%11.9%20.0%
Max Negative-20.6%-20.7%-16.0%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025805202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024213202510-K 12/31/2024
93020241105202410-Q 9/30/2024
6302024802202410-Q 6/30/2024
3312024507202410-Q 3/31/2024
12312023215202410-K 12/31/2023
93020231107202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022210202310-K 12/31/2022
93020221028202210-Q 9/30/2022
6302022805202210-Q 6/30/2022
3312022506202210-Q 3/31/2022
12312021209202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Bhatia Sangeeta N. 8292025Sell386.69266102,8601,765,240Form
1Kewalramani ReshmaCEO & President8072025Buy389.084,2901,669,15342,899,183Form
2SACHS BRUCE I 8072025Buy389.361,634636,21416,210,614Form
3ALTSHULER DAVIDEVP, Chief Scientific Officer5192025Sell424.695222,0849,887,208Form
4ALTSHULER DAVIDEVP, Chief Scientific Officer3172025Sell510.003,2311,647,81011,873,310Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.